BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15389251)

  • 1. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
    Logani S; Oliva E; Arnell PM; Amin MB; Young RH
    Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
    Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
    Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
    Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
    Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
    Kim MJ
    J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
    Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
    Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
    McCluggage WG; Young RH
    Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Suh N; Yang XJ; Tretiakova MS; Humphrey PA; Wang HL
    Mod Pathol; 2005 Sep; 18(9):1217-22. PubMed ID: 15803184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
    Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
    Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
    Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
    Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
    Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.
    Albarracin CT; Jafri J; Montag AG; Hart J; Kuan SF
    Hum Pathol; 2000 Jun; 31(6):672-7. PubMed ID: 10872659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
    Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
    Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
    Baker PM; Oliva E
    Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.